Before Treatment
Common temporary effects can include dissociation, dizziness, nausea, sedation, vertigo, anxiety, increased blood pressure, vomiting, feeling drunk, and headache. SPRAVATO is not appropriate for everyone. Older adults and people with multiple medical conditions may need additional coordination with their medical team. A clinical review should include:
Follow the clinic's instructions about eating, drinking, and medications, and confirm your transportation home. Tell the team about medication or health changes before dosing.
Individual results and coverage vary. A clinical evaluation is required.
Questions?
Our team can review treatment fit, scheduling, and next steps.
Yes. A SPRAVATO consultation does not require you to transfer the rest of your care. With your permission, BioMental can share findings and coordinate treatment with your existing mental health and medical clinicians.
Compassionate care. Science-backed results.
For Treatment-Resistant Depression
If you or someone you care about is still struggling despite medication or therapy, it does not mean you have failed. Another treatment option may help.
SPRAVATO (esketamine) is an FDA-approved nasal spray for adults with treatment-resistant depression. Esketamine is related to ketamine but is administered differently: patients use SPRAVATO under direct clinical supervision in a certified healthcare setting. For TRD, it may be used alone or with an oral antidepressant.
BioMental Clinic brings more than 20 years of psychiatric experience and nearly a decade of caring for treatment-resistant conditions. We provide a coordinated path from evaluation and insurance authorization through treatment and follow-up care.
Before treatment begins, identify changes that would make daily life feel more manageable:
SPRAVATO is an FDA-approved esketamine nasal spray for adults with treatment-resistant depression, often called TRD. TRD generally means depression has not improved enough after at least two adequate antidepressant treatments during the current episode.
Patients self-administer SPRAVATO under direct supervision. It is not dispensed for home use and is available only through certified healthcare settings participating in REMS, an FDA-required safety program.
Many traditional antidepressants act on serotonin, norepinephrine, or dopamine. SPRAVATO works differently through the brain's glutamate system.
SPRAVATO blocks NMDA receptors and is believed to promote changes in brain-cell connections, sometimes called neuroplasticity. Its exact antidepressant mechanism is not fully understood, but this different pathway may help some patients whose symptoms have not improved enough with other treatments.
You may be referred by a current clinician or contact BioMental directly. Either path begins with a coordinated clinical and practical review:
At check-in, the team confirms preparation instructions and transportation, reviews health or medication changes, and checks blood pressure.
You self-administer the nasal spray under clinical supervision. Staff guide the process and monitor how you respond.
You rest under observation for at least two hours; a support person may stay when appropriate. Your provider decides when you can leave. Do not drive or perform safety-sensitive tasks until the next day after restful sleep.
For TRD, treatment is commonly twice weekly in weeks 1-4, weekly in weeks 5-8, then weekly or every other week. Rating scales, follow-ups, daily functioning, tolerability, and preferences guide continuation and frequency. The least frequent schedule that maintains benefit is used. If symptoms return after a pause, the team can reassess restarting.
Many plans cover SPRAVATO when medical criteria are met; prior authorization is common. BioMental reviews benefits, documents prior antidepressant trials, and explains expected costs. If denied, the team can review the reason and appeal when clinically appropriate.